Deep Dive
The core claim: regulation kills
One doctor opens with a provocative statement: waiting 10 years to release a drug that already works amounts to killing people. His framing is blunt — it's not a tradeoff, it's preventable death by regulatory inaction. The counterargument lands immediately: historically, drugs that looked good in labs harmed real patients, so gatekeeping protected people. But the first doctor flips the framing. He's not arguing we should release untested drugs. He's arguing we count deaths wrong — we see the harm from early release and recoil, but we never see the deaths from withholding drugs that worked.
GLP-1s and the cost of delay
The concrete example: GLP-1 drugs like tirzepatide existed in primitive form in the 1990s but didn't reach patients until the 2020s. These are longevity drugs — older people take them and measurably die less. A 30-year delay on a weight-loss therapy that also extends lifespan, the argument goes, cost tens of millions of lives during the obesity epidemic. The regulatory burden alone is cited as a culprit: it costs a billion dollars to push a drug through trials, which creates a perverse incentive to sit on early findings. The math offered is stark: 50 million lives potentially saved if GLP-1s had been available decades earlier.
Reality check: patient consent doesn't work like theory
The second doctor pushes back hard. This entire framework assumes patients rationally assess risk — 'I'm 15% comfortable with this risk' — and then choose accordingly. That's not how medicine works in practice. Real patient conversations aren't academic. People don't show up at the clinic prepared to debate regulatory philosophy. The objection isn't that early access is always wrong; it's that the first doctor's solution (individual choice, faster approval) sounds clean only in theory. In practice, regulatory capture, inequality in access, and information asymmetry would create a messier outcome than the current system, imperfect as it is.